1h Free Analyst Time
The publisher's latest disease pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Drugs In Development, 2022, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.
Report Highlights
The publisher's latest pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 11 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.
Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of TablesList of Figures
Introduction
Report Coverage
Lassa Fever (Lassa Hemorrhagic Fever) - Overview
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development
Curevac NV
Emergent BioSolutions Inc
FUJIFILM Toyama Chemical Co Ltd
GeoVax Labs Inc
Globavir Biosciences Inc
Helix Biogen Institute
ImmunityBio Inc
Inovio Pharmaceuticals Inc
Kineta Inc
Themis Bioscience GmbH
Tonix Pharmaceuticals Holding Corp
Zalgen Labs LLC
Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles
(Ebola + Lassa Fever + Marburg) vaccine - Drug Profile
Product Description
Mechanism Of Action
(Lassa fever + rabies) vaccine - Drug Profile
Product Description
Mechanism Of Action
arevirumab-3 - Drug Profile
Product Description
Mechanism Of Action
History of Events
favipiravir - Drug Profile
Product Description
Mechanism Of Action
History of Events
GBV-006 - Drug Profile
Product Description
Mechanism Of Action
History of Events
GEOLM-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
hemorrhagic fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
INO-4500 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
Lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
lassa fever vaccine - Drug Profile
Product Description
Mechanism Of Action
lassa fever vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
lassa fever vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
lassa vaccine - Drug Profile
Product Description
Mechanism Of Action
History of Events
LHF-535 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ML-29 - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Lassa Fever - Drug Profile
Product Description
Mechanism Of Action
TNX-3500 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Vaccine for Infectious Diseases and Oncology - Drug Profile
Product Description
Mechanism Of Action
History of Events
Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects
Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones
Featured News
Oct 26, 2021: INOVIO completes enrollment of phase 1B clinical trial for its DNA vaccine candidate against Lassa fever, INO-4500, in West Africa
Jul 14, 2021: Batavia successfully uses innovative hip-vax to manufacture IAVI’s lassa fever vaccine candidate for phase I clinical trials
Jun 15, 2021: EDCTP and CEPI Funding moves IAVI's lassa fever vaccine candidate into advanced clinical development
Feb 23, 2021: INOVIO announces first subject dosed in phase 1B clinical trial for its DNA vaccine against lassa fever, INO-4500, in West Africa
Mar 25, 2020: Kineta presents clinical study results of LHF-535 at the International Conference on Antiviral Research (ICAR)
Oct 30, 2019: Themis Bioscience and CEPI trial Lassa fever vaccine
Aug 06, 2019: Kineta Secures $1.8 Million Funding Boost from Wellcome Trust on Positive Phase 1a Clinical Study Results with LHF-535
Jul 16, 2019: GeoVax announces upcoming presentation of lassa fever vaccine data
Jul 15, 2019: Kineta secures NIAID grant worth up to $5.8M to evaluate LHF-535 in Arenaviruses
May 23, 2019: Inovio doses patients in Phase I trial of Lassa virus vaccine INO-4500
Dec 11, 2018: Batavia Biosciences Partners with IAVI to Advance Development of Vaccine Against Lassa Fever
Sep 26, 2018: GeoVax awarded $2.4 million from U.S. Department of Defense to advance Lassa Fever Vaccine
Sep 15, 2018: Advanced preclinical development and production of master seed virus of GEO-LM01, a novel MVA-VLP vaccine against Lassa Fever
Sep 05, 2018: Kineta initiates first-in-human clinical trial of LHF-535 a novel therapy for lassa fever
Aug 20, 2018: Emergent and Profectus receive CEPI contract for Lassa virus vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
- Number of - Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2022
- Number of - Products under Development by Companies, 2022
- Number of - Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by FUJIFILM Toyama Chemical Co Ltd, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Globavir Biosciences Inc, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Helix Biogen Institute, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by ImmunityBio Inc, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Inovio Pharmaceuticals Inc, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Themis Bioscience GmbH, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Zalgen Labs LLC, 2022
Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, 2022 List of Figures
- Number of - Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), 2022
- Number of - Products under Development by Companies, 2022
- Number of - Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Curevac NV
- Emergent BioSolutions Inc
- FUJIFILM Toyama Chemical Co Ltd
- GeoVax Labs Inc
- Globavir Biosciences Inc
- Helix Biogen Institute
- ImmunityBio Inc
- Inovio Pharmaceuticals Inc
- Kineta Inc
- Themis Bioscience GmbH
- Tonix Pharmac
